BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pomalidomide: Phase I/II data

Data from the Phase II portion of the open-label, dose-escalation, North American Phase I/II CC-4047-MM-002 trial in 191 evaluable patients showed that oral pomalidomide plus low-dose dexamethasone led to a median PFS, the primary endpoint, of 4.7 months vs. 2.7 months for pomalidomide alone. Additionally, 34% of patients receiving pomalidomide plus dexamethasone achieved a partial response or better vs. 13% for pomalidomide alone, while an objective response, defined as a minor...

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >